Trial Profile
A Randomized, Double-blind, Placebo-controlled Phase II Study of Pazopanib Versus Placebo as Maintenance Therapy for Patients Who Have Not Progressed After First-line Chemotherapy for Advanced Soft Tissue Sarcoma (STS)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 11 Oct 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 24 Feb 2015 Planned initiation date changed from 1 Apr 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov
- 24 Feb 2015 New trial record